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INTRODUCTION
• Chemoresistant
leukemia stem cells
(LSCs) can cause
relapse in leukemia
• Doxorubicin (DXR)
has been identified
as an inhibitor of an
immune checkpoint
(IC) mechanism of
resistance
• Objective: determine
the DXR doses that
inhibit IC expression
upregulation in vitro

RESULTS

Multiple immune checkpoints show
significantly lower expression in low
dose doxorubicin treated leukemia cells
compared to cells treated with
chemotherapeutic dose doxorubicin.

METHODS
• Kasumi and Jurkat
cell lines were
treated with low and
high doses of DXR
determined by
previous kill curve
experiments
• Cells were collected
at 12h timepoints
over the course of
48h and analyzed for
expression of CTLA4, PD-1, PD-L1,
TIGIT, and TIM-3 via
flow cytometry
• Statistical analysis
was done using
Tukey’s multiple
comparisons test

• 25 nM DXR treated
Kasumi cells showed
significantly lower
CTLA-4, TIGIT, and
TIM-3 expression at
36h (p<0.0001) and
48h (p<0.001)
• 10 nM DXR treated
Jurkat cells showed
significantly lower
CTLA-4, TIGIT, and
TIM-3 expression at
36h (p<0.01) and 48h
(p<0.0001)
• TIGIT and TIM-3 also
showed lower
expression at 24h
(p<0.0001)

DISCUSSION
****: p<0.0001
***: p<0.001
**: p<0.01
*: p<0.05

Figure 1: Bar graphs showing expression of CTLA-4, TIGIT, and TIM-3 immune checkpoints in Kasumi and
Jurkat cells. Expression is measured as the percent frequency of the parent cell population detected.

Take a picture to download the
presenter’s contact information

• Results show that in
mixed cell
populations, low dose
DXR prevents the
upregulation of
multiple ICs within the
first two days of
treatment
• Overall, this presents
a promising strategy
for preventing a
mechanism of
resistance using an
established
chemotherapeutic
agent

